Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide plus 5:2 intermittent fasting after stopping weekly weight-loss injectables (LIFE)
ChiCTR2600128784Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liraglutide in Overweight and obesity (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Percentage change in body weight from baseline at week 12. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on ChiCTR2600128784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128784.